Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

[Comprehensive analysis of disease-related glycosylation, leading to glyco-therapy].

Miyoshi E, Fujii H, Shinzaki S, Tanemura M, Kamada Y.

Seikagaku. 2017 Apr;89(2):264-8. Japanese. No abstract available.

PMID:
29624994
2.

Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.

Bilousova T, Elias C, Miyoshi E, Alam MP, Zhu C, Campagna J, Vadivel K, Jagodzinska B, Gylys KH, John V.

Biochem Biophys Res Commun. 2018 May 23;499(4):751-757. doi: 10.1016/j.bbrc.2018.03.209. Epub 2018 Apr 9.

PMID:
29604274
3.

Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation.

Nishino K, Koda S, Kataoka N, Takamatsu S, Nakano M, Ikeda S, Kamamatsu Y, Morishita K, Moriwaki K, Eguchi H, Yamamoto E, Kikkawa F, Tomita Y, Kamada Y, Miyoshi E.

Oncotarget. 2018 Jan 29;9(16):12732-12744. doi: 10.18632/oncotarget.24332. eCollection 2018 Feb 27.

4.

The Rab11-binding protein RELCH/KIAA1468 controls intracellular cholesterol distribution.

Sobajima T, Yoshimura SI, Maeda T, Miyata H, Miyoshi E, Harada A.

J Cell Biol. 2018 May 7;217(5):1777-1796. doi: 10.1083/jcb.201709123. Epub 2018 Mar 7.

5.

Self-monitoring of urinary salt excretion as a method of salt-reduction education: a parallel, randomized trial involving two groups.

Yasutake K, Miyoshi E, Misumi Y, Kajiyama T, Fukuda T, Ishii T, Moriguchi R, Murata Y, Ohe K, Enjoji M, Tsuchihashi T.

Public Health Nutr. 2018 Aug;21(12):2164-2173. doi: 10.1017/S1368980018000095. Epub 2018 Feb 20.

PMID:
29458447
6.

Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.

Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD).

Hepatol Commun. 2017 Aug 16;1(8):780-791. doi: 10.1002/hep4.1080. eCollection 2017 Oct.

7.

Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.

Vecchia DD, Kanazawa LKS, Wendler E, de Almeida Soares Hocayen P, Bruginski E, Campos FR, Stern CAJ, Vital MABF, Miyoshi E, Wöhr M, Schwarting RKW, Andreatini R.

Behav Brain Res. 2018 Apr 16;342:1-10. doi: 10.1016/j.bbr.2017.12.041. Epub 2018 Jan 4.

PMID:
29307665
8.

Depression in Parkinson's Disease: The Contribution from Animal Studies.

Fontoura JL, Baptista C, Pedroso FB, Pochapski JA, Miyoshi E, Ferro MM.

Parkinsons Dis. 2017;2017:9124160. doi: 10.1155/2017/9124160. Epub 2017 Oct 11. Review.

9.

A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.

Furukawa K, Tanemura M, Miyoshi E, Eguchi H, Nagano H, Matsunami K, Nagaoka S, Yamada D, Asaoka T, Noda T, Wada H, Kawamoto K, Goto K, Taniyama K, Mori M, Doki Y.

PLoS One. 2017 Oct 27;12(10):e0184901. doi: 10.1371/journal.pone.0184901. eCollection 2017.

10.

Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer.

Hata T, Kawamoto K, Eguchi H, Kamada Y, Takamatsu S, Maekawa T, Nagaoka S, Yamada D, Iwagami Y, Asaoka T, Noda T, Wada H, Gotoh K, Masamune A, Miyoshi E, Mori M, Doki Y.

Pancreas. 2017 Nov/Dec;46(10):1259-1266. doi: 10.1097/MPA.0000000000000943.

PMID:
28991878
11.

Core fucose is critical for CD14-dependent Toll-like receptor 4 signaling.

Iijima J, Kobayashi S, Kitazume S, Kizuka Y, Fujinawa R, Korekane H, Shibata T, Saitoh SI, Akashi-Takamura S, Miyake K, Miyoshi E, Taniguchi N.

Glycobiology. 2017 Nov 1;27(11):1006-1015. doi: 10.1093/glycob/cwx075.

PMID:
28973141
12.

Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.

Betesh L, Comunale MA, Wang M, Liang H, Hafner J, Karabudak A, Giama NH, Moser CD, Miyoshi E, Roberts LR, Block TM, Mehta A.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201600141. Epub 2017 Jul 10.

13.

Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system.

Kusama K, Okamoto Y, Saito K, Kasahara T, Murata T, Ueno Y, Kobayashi Y, Kamada Y, Miyoshi E.

Glycoconj J. 2017 Aug;34(4):537-544. doi: 10.1007/s10719-017-9772-9. Epub 2017 Apr 28.

14.

Heterogeneity in homogeneous nucleation from billion-atom molecular dynamics simulation of solidification of pure metal.

Shibuta Y, Sakane S, Miyoshi E, Okita S, Takaki T, Ohno M.

Nat Commun. 2017 Apr 5;8(1):10. doi: 10.1038/s41467-017-00017-5.

15.

A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology.

Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E.

J Biochem. 2017 May 1;161(5):409-415. doi: 10.1093/jb/mvx010.

PMID:
28338836
16.

Development of α1,6-fucosyltransferase inhibitors through the diversity-oriented syntheses of GDP-fucose mimics using the coupling between alkyne and sulfonyl azide.

Manabe Y, Kasahara S, Takakura Y, Yang X, Takamatsu S, Kamada Y, Miyoshi E, Yoshidome D, Fukase K.

Bioorg Med Chem. 2017 Jun 1;25(11):2844-2850. doi: 10.1016/j.bmc.2017.02.036. Epub 2017 Feb 28.

PMID:
28284868
17.

Hepatic aberrant glycosylation by N-acetylglucosaminyltransferase V accelerates HDL assembly.

Kamada Y, Kida S, Hirano KI, Yamaguchi S, Suzuki A, Hashimoto C, Kimura A, Sato M, Fujii H, Sobajima T, Yamamoto A, Ebisutani Y, Takamatsu S, Shinzaki S, Yoshida Y, Yamada M, Nagasaka H, Takehara T, Miyoshi E.

Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G859-G868. doi: 10.1152/ajpgi.00231.2016. Epub 2016 Sep 22.

18.

Application of glycoscience to the early detection of pancreatic cancer.

Miyoshi E, Kamada Y.

Cancer Sci. 2016 Oct;107(10):1357-1362. doi: 10.1111/cas.13011. Epub 2016 Sep 2. Review.

19.

Establishment of mouse Mac-2 binding protein enzyme-linked immunosorbent assay and its application for mouse chronic liver disease models.

Iwata A, Kamada Y, Ebisutani Y, Yamamoto A, Ueda Y, Arai H, Fujii H, Takamatsu S, Maruyama N, Maeda M, Takehara T, Miyoshi E.

Hepatol Res. 2017 Aug;47(9):902-909. doi: 10.1111/hepr.12819. Epub 2016 Oct 13.

PMID:
27615366
20.

O-mannosylation and N-glycosylation: two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer.

Carvalho S, Oliveira T, Bartels MF, Miyoshi E, Pierce M, Taniguchi N, Carneiro F, Seruca R, Reis CA, Strahl S, Pinho SS.

Oncotarget. 2016 Oct 4;7(40):65231-65246. doi: 10.18632/oncotarget.11245.

21.

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.

Fujita K, Hayashi T, Matsuzaki K, Nakata W, Masuda M, Kawashima A, Ujike T, Nagahara A, Tsuchiya M, Kobayashi Y, Nojima S, Uemura M, Morii E, Miyoshi E, Nonomura N.

Oncotarget. 2016 Aug 30;7(35):56643-56649. doi: 10.18632/oncotarget.10987.

22.

Comparison of a salt check sheet with 24-h urinary salt excretion measurement in local residents.

Yasutake K, Miyoshi E, Kajiyama T, Umeki Y, Misumi Y, Horita N, Murata Y, Ohe K, Enjoji M, Tsuchihashi T.

Hypertens Res. 2016 Dec;39(12):879-885. doi: 10.1038/hr.2016.79. Epub 2016 Jul 7.

PMID:
27383507
23.

Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy.

Takamatsu S, Shimomura M, Kamada Y, Maeda H, Sobajima T, Hikita H, Iijima M, Okamoto Y, Misaki R, Fujiyama K, Nagamori S, Kanai Y, Takehara T, Ueda K, Kuroda S, Miyoshi E.

Glycobiology. 2016 Nov;26(11):1180-1189. doi: 10.1093/glycob/cww067. Epub 2016 Jun 21.

PMID:
27329181
24.

Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.

Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E.

World J Gastroenterol. 2016 May 7;22(17):4403-10. doi: 10.3748/wjg.v22.i17.4403.

25.

Occurrence of free sialyl oligosaccharides related to N-glycans (sialyl free N-glycans) in animal sera.

Seino J, Fujihira H, Nakakita SI, Masahara-Negishi Y, Miyoshi E, Hirabayashi J, Suzuki T.

Glycobiology. 2016 Oct;26(10):1072-1085. doi: 10.1093/glycob/cww048. Epub 2016 Apr 21.

PMID:
27102284
26.

Glyco-redox, a link between oxidative stress and changes of glycans: Lessons from research on glutathione, reactive oxygen and nitrogen species to glycobiology.

Taniguchi N, Kizuka Y, Takamatsu S, Miyoshi E, Gao C, Suzuki K, Kitazume S, Ohtsubo K.

Arch Biochem Biophys. 2016 Apr 1;595:72-80. doi: 10.1016/j.abb.2015.11.024.

PMID:
27095220
27.

Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects.

Kamada Y, Hashimoto R, Yamamori H, Yasuda Y, Takehara T, Fujita Y, Hashimoto K, Miyoshi E.

BBA Clin. 2016 Feb 23;5:101-7. doi: 10.1016/j.bbacli.2016.02.004. eCollection 2016 Jun.

28.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.

Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, Okumura A, Fujioka Y, Urakawa R, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Miyoshi E, Hirata T, Kumanogoh A, Sugiyama H, Hosen N.

PLoS One. 2016 Mar 24;11(3):e0152326. doi: 10.1371/journal.pone.0152326. eCollection 2016.

29.

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.

Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T.

PLoS One. 2016 Mar 22;11(3):e0151828. doi: 10.1371/journal.pone.0151828. eCollection 2016.

30.

Core Fucosylation on T Cells, Required for Activation of T-Cell Receptor Signaling and Induction of Colitis in Mice, Is Increased in Patients With Inflammatory Bowel Disease.

Fujii H, Shinzaki S, Iijima H, Wakamatsu K, Iwamoto C, Sobajima T, Kuwahara R, Hiyama S, Hayashi Y, Takamatsu S, Uozumi N, Kamada Y, Tsujii M, Taniguchi N, Takehara T, Miyoshi E.

Gastroenterology. 2016 Jun;150(7):1620-1632. doi: 10.1053/j.gastro.2016.03.002. Epub 2016 Mar 8.

PMID:
26965517
31.

A glycoproteomic approach to identify novel glycomarkers for cancer stem cells.

Sawanobori A, Moriwaki K, Takamatsu S, Kamada Y, Miyoshi E.

Proteomics. 2016 Dec;16(24):3073-3080. doi: 10.1002/pmic.201500472. Epub 2016 May 9. Review.

PMID:
26949200
32.

Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.

Ueda M, Kamada Y, Takamatsu S, Shimomura M, Maekawa T, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kobayashi Y, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E.

Pancreatology. 2016 Mar-Apr;16(2):238-43. doi: 10.1016/j.pan.2016.01.004. Epub 2016 Jan 21.

PMID:
26897254
33.

Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer.

Takahashi S, Sugiyama T, Shimomura M, Kamada Y, Fujita K, Nonomura N, Miyoshi E, Nakano M.

Glycoconj J. 2016 Jun;33(3):471-82. doi: 10.1007/s10719-016-9653-7. Epub 2016 Feb 11.

PMID:
26869352
34.

Elevation of CA19-9-Related Novel Marker, Core 1 Sialyl Lewis A, in Sera of Adenocarcinoma Patients Verified by a SRM-Based Method.

Tanaka-Okamoto M, Yabu M, Mukai M, Takahashi H, Fujiwara Y, Ohue M, Kamada Y, Miyoshi E, Miyamoto Y.

J Proteome Res. 2016 Jan 4;15(1):152-65. doi: 10.1021/acs.jproteome.5b00893. Epub 2015 Dec 17.

PMID:
26641888
35.

Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.

Tanemura M, Miyoshi E, Nagano H, Eguchi H, Matsunami K, Taniyama K, Hatanaka N, Akamatsu H, Mori M, Doki Y.

World J Gastroenterol. 2015 Oct 28;21(40):11396-410. doi: 10.3748/wjg.v21.i40.11396. Review.

36.

Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease.

Miyoshi E, Shinzaki S, Fujii H, Iijima H, Kamada Y, Takehara T.

Proteomics Clin Appl. 2016 Apr;10(4):384-90. doi: 10.1002/prca.201500089. Epub 2016 Mar 11. Review.

PMID:
26427763
37.

N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis.

Shinzaki S, Ishii M, Fujii H, Iijima H, Wakamatsu K, Kawai S, Shiraishi E, Hiyama S, Inoue T, Hayashi Y, Kuwahara R, Takamatsu S, Kamada Y, Morii E, Tsujii M, Takehara T, Miyoshi E.

J Gastroenterol. 2016 Apr;51(4):357-69. doi: 10.1007/s00535-015-1119-3. Epub 2015 Sep 8.

PMID:
26349931
38.

A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.

Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.

Hepatology. 2015 Nov;62(5):1433-43. doi: 10.1002/hep.28002. Epub 2015 Aug 25.

PMID:
26199205
39.

Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer.

Carvalho S, Catarino TA, Dias AM, Kato M, Almeida A, Hessling B, Figueiredo J, Gärtner F, Sanches JM, Ruppert T, Miyoshi E, Pierce M, Carneiro F, Kolarich D, Seruca R, Yamaguchi Y, Taniguchi N, Reis CA, Pinho SS.

Oncogene. 2016 Mar 31;35(13):1619-31. doi: 10.1038/onc.2015.225. Epub 2015 Jul 20.

40.

Abnormal Cerebrovascular Reactivity in Patients with Parkinson's Disease.

Camargo CH, Martins EA, Lange MC, Hoffmann HA, Luciano JJ, Young Blood MR, Schafranski MD, Ferro MM, Miyoshi E.

Parkinsons Dis. 2015;2015:523041. doi: 10.1155/2015/523041. Epub 2015 Jun 16.

41.

Lectin Microarray-Based Sero-Biomarker Verification Targeting Aberrant O-Linked Glycosylation on Mucin 1.

Matsuda A, Kuno A, Nakagawa T, Ikehara Y, Irimura T, Yamamoto M, Nakanuma Y, Miyoshi E, Nakamori S, Nakanishi H, Viwatthanasittiphong C, Srivatanakul P, Miwa M, Shoda J, Narimatsu H.

Anal Chem. 2015 Jul 21;87(14):7274-81. doi: 10.1021/acs.analchem.5b01329. Epub 2015 Jul 7.

PMID:
26091356
42.

Ectopic expression of N-acetylglucosaminyltransferase V accelerates hepatic triglyceride synthesis.

Kamada Y, Ebisutani Y, Kida S, Mizutani K, Akita M, Yamamoto A, Fujii H, Sobajima T, Terao N, Takamatsu S, Yoshida Y, Takehara T, Miyoshi E.

Hepatol Res. 2016 Mar;46(3):E118-29. doi: 10.1111/hepr.12541. Epub 2015 Jul 14.

PMID:
26041473
43.

Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma.

Kato A, Yutani M, Terao M, Kimura A, Itoi S, Murota H, Miyoshi E, Katayama I.

Exp Dermatol. 2015 Aug;24(8):585-90. doi: 10.1111/exd.12730. Epub 2015 May 26.

PMID:
25876794
44.

Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin.

Shimomura M, Nakayama K, Azuma K, Terao N, Nishino K, Takamatsu S, Nakano M, Takahashi S, Kobayashi Y, Murata K, Kamada Y, Miyoshi E.

Clin Chim Acta. 2015 Jun 15;446:30-6. doi: 10.1016/j.cca.2015.03.037. Epub 2015 Apr 7.

PMID:
25861849
45.

Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.

Terao N, Takamatsu S, Minehira T, Sobajima T, Nakayama K, Kamada Y, Miyoshi E.

World J Gastroenterol. 2015 Apr 7;21(13):3876-87. doi: 10.3748/wjg.v21.i13.3876.

46.

Value of fetuin-A as a predictor of liver fibrosis in patients with nonalcoholic fatty liver disease. Author's reply.

Kamada Y, Miyoshi E.

Liver Int. 2015 Aug;35(8):2062. doi: 10.1111/liv.12833. Epub 2015 Apr 7. No abstract available.

PMID:
25809239
47.

Loss of α1,6-fucosyltransferase suppressed liver regeneration: implication of core fucose in the regulation of growth factor receptor-mediated cellular signaling.

Wang Y, Fukuda T, Isaji T, Lu J, Gu W, Lee HH, Ohkubo Y, Kamada Y, Taniguchi N, Miyoshi E, Gu J.

Sci Rep. 2015 Feb 5;5:8264. doi: 10.1038/srep08264.

48.

Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.

Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E.

Liver Int. 2015 Mar;35(3):925-35. doi: 10.1111/liv.12478. Epub 2014 Feb 26.

PMID:
25627311
49.

Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.

Honma R, Kinoshita I, Miyoshi E, Tomaru U, Matsuno Y, Shimizu Y, Takeuchi S, Kobayashi Y, Kaga K, Taniguchi N, Dosaka-Akita H.

Oncology. 2015;88(5):298-308. doi: 10.1159/000369495. Epub 2015 Jan 7.

PMID:
25572677
50.

N-acetylglucosaminyltransferase V exacerbates concanavalin A-induced hepatitis in mice.

Kamada Y, Sato M, Kida S, Akita M, Mizutani K, Fujii H, Sobajima T, Yoshida Y, Shinzaki S, Takamatsu S, Takehara T, Miyoshi E.

Mol Med Rep. 2015 May;11(5):3573-84. doi: 10.3892/mmr.2015.3168. Epub 2015 Jan 8.

PMID:
25572342

Supplemental Content

Loading ...
Support Center